Fluorometric Quantification of Total Cell-Free DNA as a Prognostic Biomarker in Non-Small-Cell Lung Cancer Patients Treated with Immune Checkpoint Blockade.
NSCLC
cfDNA
immunotherapy
prognosis
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
26 Jun 2023
26 Jun 2023
Historique:
received:
30
05
2023
revised:
22
06
2023
accepted:
23
06
2023
medline:
14
7
2023
pubmed:
14
7
2023
entrez:
14
7
2023
Statut:
epublish
Résumé
The present study aimed to investigate the potential of basal cell-free fluorometric DNA (cfDNA) quantification as a prognostic biomarker in advanced non-small cell lung cancer (NSCLC) patients treated with an Immune Checkpoint Blockade (ICB). A discovery and validation cohort of 61 and 31 advanced lung cancer patients treated with ICB were included in this study. Quantification of cfDNA concentration was performed before the start of the treatment and patients were followed up for a median of 34 (30-40) months. The prognostic predicted value of cfDNA was evaluated based on ROC, and Cox regression was conducted via univariate and multivariate analyses to estimate the hazard ratio. We observed that a cfDNA cut-off of 0.55 ng/µL before the ICB determines the overall survival of patients with a log rank
Identifiants
pubmed: 37444467
pii: cancers15133357
doi: 10.3390/cancers15133357
pmc: PMC10341133
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI18/01592
Organisme : Instituto de Salud Carlos III
ID : PI22/01816
Organisme : Sociedad Española de Oncología Médica
ID : SEOM21
Organisme : Regional Government of Andalusia
ID : PI-0121-2020
Organisme : Regional Government of Andalusia
ID : RH-0090-2020
Organisme : Andalusian Health Service
ID : 0263/2017
Organisme : Regional Government of Andalusia
ID : ProyExcel_01002
Organisme : Spanish Group of Melanoma
ID : Award for Best Research Project 2020
Organisme : Fundación Bancaria Unicaja
ID : C19048
Organisme : Asociación Española Contra el Cáncer
ID : AECC 2020
Organisme : Andalusia-Roche Network Mixed Alliance in Precision Medical Oncology
ID : AC20057
Références
Cell. 2017 Feb 9;168(4):707-723
pubmed: 28187290
Nat Rev Cancer. 2011 Jun;11(6):426-37
pubmed: 21562580
JAMA Oncol. 2022 Dec 1;8(12):1830-1839
pubmed: 36264554
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Ann Oncol. 2022 Sep;33(9):929-938
pubmed: 35680043
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
J Clin Oncol. 2004 Oct 15;22(20):4157-64
pubmed: 15483026
J Immunother Cancer. 2018 Nov 23;6(1):128
pubmed: 30470252
Cancers (Basel). 2022 Jul 11;14(14):
pubmed: 35884434
JAMA. 2019 Jan 15;321(2):131-133
pubmed: 30566194
J Nucl Med. 2017 Nov;58(11):1764-1769
pubmed: 28450567
Mol Oncol. 2021 Nov;15(11):2923-2940
pubmed: 34465006
Sci Rep. 2021 Mar 3;11(1):5040
pubmed: 33658587
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295929
Pediatr Res. 2023 Jan 16;:
pubmed: 36646885
Eur J Cancer. 2018 Jan;88:1-9
pubmed: 29175734
Ann Oncol. 2023 May;34(5):468-476
pubmed: 36863484
ESMO Open. 2021 Jun;6(3):100124
pubmed: 33940346
J Natl Cancer Inst. 2009 Nov 4;101(21):1446-52
pubmed: 19815849
Cell Res. 2014 Jun;24(6):766-9
pubmed: 24710597
Eur J Cancer. 2005 Aug;41(12):1690-6
pubmed: 16043346
Int J Cancer. 2019 Apr 15;144(8):1941-1953
pubmed: 30350310
Ann Oncol. 2019 Oct 1;30(10):1653-1659
pubmed: 31435660
J Clin Invest. 2022 Jun 15;132(12):
pubmed: 35703177
Chest. 2022 Nov;162(5):1006-1016
pubmed: 35714708
Cancer Biol Ther. 2019;20(8):1057-1067
pubmed: 30990132
JAMA Oncol. 2016 Sep 1;2(9):1217-22
pubmed: 27310809
Immunity. 2020 May 19;52(5):856-871.e8
pubmed: 32289253
JAMA Oncol. 2023 Mar 1;9(3):419-429
pubmed: 36520421
Nat Commun. 2018 Nov 29;9(1):5068
pubmed: 30498206
Nat Immunol. 2014 Nov;15(11):1017-25
pubmed: 25217981
Immunity. 2017 Jan 17;46(1):15-28
pubmed: 28099862
J Immunother Cancer. 2023 Feb;11(2):
pubmed: 36792122
Cancer Metastasis Rev. 2016 Sep;35(3):347-76
pubmed: 27392603